Compare Stocks: RNTX, PRLD, FATE, and FULC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FATE Fate Therapeutics	$2.18 +2.3%	$2.46	$0.95 ▼ $3.23	$255.22M	2.52	1.66 million shs	770,744 shs
FULC Fulcrum Therapeutics	$3.77 +0.5%	$3.79	$2.83 ▼ $15.74	$286.11M	2.63	1.44 million shs	1.80 million shs
PRLD Prelude Therapeutics	$3.89 +0.3%	$4.94	$1.15 ▼ $6.83	$309.64M	0.97	516,939 shs	341,648 shs
RNTX Rein Therapeutics	$0.79 +3.2%	$0.79	$0.69 ▼ $2.18	$66.36M	1.35	367,084 shs	307,535 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FATE Fate Therapeutics	+2.35%	-6.03%	-10.66%	-29.68%	+44.37%
FULC Fulcrum Therapeutics	+0.53%	+2.17%	-1.82%	+7.71%	-60.85%
PRLD Prelude Therapeutics	+0.26%	+5.99%	-23.58%	-18.96%	+173.94%
RNTX Rein Therapeutics	+3.21%	-0.84%	-4.05%	-18.98%	-42.88%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FATE Fate Therapeutics	$2.18 +2.3%	$2.46	$0.95 ▼ $3.23	$255.22M	2.52	1.66 million shs	770,744 shs
FULC Fulcrum Therapeutics	$3.77 +0.5%	$3.79	$2.83 ▼ $15.74	$286.11M	2.63	1.44 million shs	1.80 million shs
PRLD Prelude Therapeutics	$3.89 +0.3%	$4.94	$1.15 ▼ $6.83	$309.64M	0.97	516,939 shs	341,648 shs
RNTX Rein Therapeutics	$0.79 +3.2%	$0.79	$0.69 ▼ $2.18	$66.36M	1.35	367,084 shs	307,535 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FATE Fate Therapeutics	+2.35%	-6.03%	-10.66%	-29.68%	+44.37%
FULC Fulcrum Therapeutics	+0.53%	+2.17%	-1.82%	+7.71%	-60.85%
PRLD Prelude Therapeutics	+0.26%	+5.99%	-23.58%	-18.96%	+173.94%
RNTX Rein Therapeutics	+3.21%	-0.84%	-4.05%	-18.98%	-42.88%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FATE Fate Therapeutics	2.38	Hold	$5.90	170.64% Upside
FULC Fulcrum Therapeutics	1.75	Reduce	$8.20	117.51% Upside
PRLD Prelude Therapeutics	2.50	Moderate Buy	$8.75	124.94% Upside
RNTX Rein Therapeutics	2.25	Hold	$6.00	655.67% Upside

Current Analyst Ratings Breakdown

Latest RNTX, PRLD, FATE, and FULC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/17/2026	PRLD Prelude Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$12.00
8/21/2026	RNTX Rein Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/18/2026	RNTX Rein Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/14/2026	FATE Fate Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$6.00 ➝ $8.00
8/14/2026	FATE Fate Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$2.50 ➝ $3.50
8/14/2026	FATE Fate Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$7.00
8/7/2026	FATE Fate Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/3/2026	RNTX Rein Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/29/2026	PRLD Prelude Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/29/2026	PRLD Prelude Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00
7/20/2026	RNTX Rein Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$4.00

(Data available from 10/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FATE Fate Therapeutics	$6.65M	39.28	N/A	N/A	$1.80 per share	1.21
FULC Fulcrum Therapeutics	$80M	3.60	N/A	N/A	$6.45 per share	0.58
PRLD Prelude Therapeutics	$12.14M	25.57	N/A	N/A	$1.09 per share	3.57
RNTX Rein Therapeutics	N/A	N/A	$0.06 per share	13.45	($1.07) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FATE Fate Therapeutics	-$136.32M	-$1.05	N/A	N/A	N/A	-1,941.09%	-65.08%	-41.73%	10/29/2026 (Estimated)
FULC Fulcrum Therapeutics	-$74.88M	-$1.21	N/A	N/A	N/A	N/A	-25.38%	-24.15%	10/29/2026 (Estimated)
PRLD Prelude Therapeutics	-$99.50M	-$0.73	N/A	N/A	N/A	N/A	-75.35%	-44.39%	11/11/2026 (Estimated)
RNTX Rein Therapeutics	-$49.87M	-$1.72	N/A	N/A	N/A	N/A	N/A	-63.69%	N/A

Latest RNTX, PRLD, FATE, and FULC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/29/2026	Q3 2026	FULC Fulcrum Therapeutics	-$0.0745	N/A	N/A	N/A	N/A	N/A
8/14/2026	Q2 2026	RNTX Rein Therapeutics	-$0.27	-$0.10	+$0.17	-$0.10	N/A	N/A
8/13/2026	Q2 2026	FATE Fate Therapeutics	-$0.2536	-$0.25	+$0.0036	-$0.25	$1.94 million	$2.08 million
8/11/2026	Q2 2026	PRLD Prelude Therapeutics	-$0.1967	-$0.14	+$0.0567	-$0.14	$5.70 million	$5.70 million
7/30/2026	Q2 2026	FULC Fulcrum Therapeutics	-$0.2433	-$0.34	-$0.0967	-$0.34	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
FATE Fate Therapeutics	N/A	N/A	N/A	N/A	N/A
FULC Fulcrum Therapeutics	N/A	N/A	N/A	N/A	N/A
PRLD Prelude Therapeutics	N/A	N/A	N/A	N/A	N/A
RNTX Rein Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FATE Fate Therapeutics	N/A	4.85	4.85
FULC Fulcrum Therapeutics	N/A	31.35	31.35
PRLD Prelude Therapeutics	N/A	4.07	4.07
RNTX Rein Therapeutics	N/A	4.27	4.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FATE Fate Therapeutics	97.54%
FULC Fulcrum Therapeutics	89.83%
PRLD Prelude Therapeutics	79.72%
RNTX Rein Therapeutics	90.89%

Insider Ownership

Company	Insider Ownership
FATE Fate Therapeutics	4.74%
FULC Fulcrum Therapeutics	7.30%
PRLD Prelude Therapeutics	49.20%
RNTX Rein Therapeutics	1.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FATE Fate Therapeutics	161	119.82 million	114.14 million	Optionable
FULC Fulcrum Therapeutics	55	76.30 million	70.73 million	Optionable
PRLD Prelude Therapeutics	79	79.80 million	40.54 million	Optionable
RNTX Rein Therapeutics	10	86.27 million	84.97 million	N/A

RNTX, PRLD, FATE, and FULC Headlines

Recent News About These Companies

Rein Therapeutics Inc. (NASDAQ:RNTX) Receives Average Rating of "Hold" from Analysts

October 3, 2026 | marketbeat.com

Rein Therapeutics (NASDAQ:RNTX) Shares Up 9.6% - Here's Why

September 29, 2026 | marketbeat.com

Rein Therapeutics to Present Late-Breaking Poster at the European Respiratory Society (ERS) 2026 Congress

September 4, 2026 | globenewswire.com

Rein Therapeutics to Present at Upcoming September Investor Conferences

September 3, 2026 | globenewswire.com

Here's Why You Should Add RNTX Stock to Your Portfolio Now

September 3, 2026 | zacks.com

Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis

August 20, 2026 | globenewswire.com

Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

August 14, 2026 | globenewswire.com

Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications

August 4, 2026 | finance.yahoo.com

Rein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries

July 21, 2026 | globenewswire.com

Rein Therapeutics (RNTX) Stock Forecast & Price Target

July 17, 2026 | investing.com

Rein Therapeutics, Inc

June 29, 2026 | edition.cnn.com

All You Need to Know About Rein Therapeutics Inc. (RNTX) Rating Upgrade to Buy

June 17, 2026 | zacks.com

Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom

June 11, 2026 | globenewswire.com

Rein Therapeutics Inc RNTX

June 7, 2026 | morningstar.comM

Rein Therapeutics (NASDAQ:RNTX) Director Buys $16,747.50 in Stock

May 29, 2026 | insidertrades.com

Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option

May 18, 2026 | globenewswire.com

Insider Buying: Rein Therapeutics (NASDAQ:RNTX) Insider Purchases 25,000 Shares of Stock

May 14, 2026 | insidertrades.com

Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock

April 30, 2026 | globenewswire.com

Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis

April 29, 2026 | globenewswire.com

Rein Therapeutics Stock Short Interest Report | NASDAQ:RNTX | Benzinga

April 14, 2026 | benzinga.com

Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis

March 3, 2026 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNTX, PRLD, FATE, and FULC Company Descriptions

Fate Therapeutics NASDAQ:FATE

$2.18 +0.05 (+2.35%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$2.17 -0.01 (-0.60%)

As of 10/9/2026 07:56 PM Eastern

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Fulcrum Therapeutics NASDAQ:FULC

$3.77 +0.02 (+0.53%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$3.77 0.00 (0.00%)

As of 10/9/2026 04:38 PM Eastern

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Prelude Therapeutics NASDAQ:PRLD

$3.89 +0.01 (+0.26%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$3.90 +0.00 (+0.13%)

As of 10/9/2026 04:38 PM Eastern

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Rein Therapeutics NASDAQ:RNTX

$0.79 +0.02 (+3.21%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$0.80 +0.00 (+0.13%)

As of 10/9/2026 05:30 PM Eastern

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RNTX, PRLD, FATE, and FULC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RNTX, PRLD, FATE, and FULC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RNTX, PRLD, FATE, and FULC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNTX, PRLD, FATE, and FULC Company Descriptions

Fate Therapeutics NASDAQ:FATE

Fulcrum Therapeutics NASDAQ:FULC

Prelude Therapeutics NASDAQ:PRLD

Rein Therapeutics NASDAQ:RNTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RNTX, PRLD, FATE, and FULC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RNTX, PRLD, FATE, and FULC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RNTX, PRLD, FATE, and FULC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNTX, PRLD, FATE, and FULC Company Descriptions

Fate Therapeutics NASDAQ:FATE

Fulcrum Therapeutics NASDAQ:FULC

Prelude Therapeutics NASDAQ:PRLD

Rein Therapeutics NASDAQ:RNTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools